StockData
Summit Therapeutics Inc. logo

Summit Therapeutics Inc. (SMMT) stock

SMMTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$10.50−0.17 (-1.59%)

Close on Nov 18, 2026Market cap $8.38BP/E –Yield –

Summit Therapeutics total assets

Total assets on the balance sheet at the end of each period.

Summit Therapeutics's total assets was $752.19M at Jun 30, 2026. For fiscal 2025 it was $751.18M, up 72.5% from the year before. The highest annual figure on record is $751.18M in fiscal 2025.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$751.18M+72.5%
FY2024Dec 31, 2024$435.56M+114.6%
FY2023Dec 31, 2023$202.95M-69.4%
FY2022Dec 31, 2022$664.17M+485.8%
FY2021Dec 31, 2021$113.37M–

Quarterly total assets

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q2 FY2026CQ2 2026Jun 30, 2026$752.19M+132.1%
Q1 FY2026CQ1 2026Mar 31, 2026$647.86M+68.8%
Q4 FY2025CQ4 2025Dec 31, 2025$751.18M+72.5%
Q3 FY2025CQ3 2025Sep 30, 2025$261.73M-48.0%
Q2 FY2025CQ2 2025Jun 30, 2025$324.04M-5.2%
Q1 FY2025CQ1 2025Mar 31, 2025$383.82M+117.1%
Q4 FY2024CQ4 2024Dec 31, 2024$435.56M+114.6%
Q3 FY2024CQ3 2024Sep 30, 2024$502.85M+130.2%
Q2 FY2024CQ2 2024Jun 30, 2024$341.86M+44.0%
Q1 FY2024CQ1 2024Mar 31, 2024$176.78M-30.6%
Q4 FY2023CQ4 2023Dec 31, 2023$202.95M-69.4%
Q3 FY2023CQ3 2023Sep 30, 2023$218.48M+40.7%
Q2 FY2023CQ2 2023Jun 30, 2023$237.37M+148.0%
Q1 FY2023CQ1 2023Mar 31, 2023$254.90M+118.8%
Q4 FY2022CQ4 2022Dec 31, 2022$664.17M+485.8%
Q3 FY2022CQ3 2022Sep 30, 2022$155.33M+20.7%
Q2 FY2022CQ2 2022Jun 30, 2022$95.72M-34.2%
Q1 FY2022CQ1 2022Mar 31, 2022$116.47M-17.3%
Q4 FY2021CQ4 2021Dec 31, 2021$113.37M–
Q3 FY2021CQ3 2021Sep 30, 2021$128.67M–
Q2 FY2021CQ2 2021Jun 30, 2021$145.52M–
Q1 FY2021CQ1 2021Mar 31, 2021$140.79M–

More Summit Therapeutics figures

See a number that looks wrong?